UK-based medical hashish cultivator Glass Pharms has introduced the launch of a brand new vary of own-branded ‘cannabis-based merchandise for medicinal use’ (CBPMs).
Glass Pharms has now launched three merchandise, which will likely be accessible in quite a few UK pharmacies within the close to future.
It comes simply weeks after it grew to become the primary UK cultivator since medical hashish was legalised in 2018 to ship domestically grown product to sufferers.
Whereas extra own-branded merchandise are stated to be within the works, Glass Pharms assured Enterprise of Hashish that its focus stays on offering flower for third-party clients.
What occurred?
As we speak, the Wiltshire-based firm introduced the launch of three new CBPMs to the market after working with an unnamed ‘UK pharmaceutical manufacturing accomplice’ to finalise the merchandise.
These will include a high-CBD flower that comprises lower than 1% THC, and two high-THC strains at completely different value factors.
One of many key drivers of this new enterprise was to allow Glass Pharms to carry new cultivars to market, particularly its high-CBD providing.
In line with a current examine printed by the College of Colorado Boulder, its CBD-dominant ratio could also be more practical in treating nervousness than larger THC strains.
Glass Pharms CEO, James Duckenfield, stated: “In addition to producing high-THC hashish flower, we’ve got a dedication to carry CBD-containing medical hashish flower to the UK market as we consider it provides prescribers choices for cannabis-naive sufferers that may in any other case be lacking.
“Cautious titration of THC content material has been proven to enhance the preliminary affected person expertise and led to higher outcomes for brand new customers of medical hashish.”
Alongside this, Glass Pharms will likely be providing two high-THC strains. The primary, described as an ‘fascinating cultivar’ containing 17% THC and a couple of% CBG, will likely be at an ‘entry degree’ value level.
The second will likely be a high-terpene, high-THC (20%) cultivar at a barely larger value level.
Whereas Glass Pharms didn’t specify the place these new strains could be accessible to buy, it stated it was specializing in making them accessible in pharmacies quite than clinics.
New enterprise, however not new route
The launch of its own-branded merchandise has reportedly been within the works for a while, and comes simply weeks after the corporate introduced a big milestone each for its personal enterprise, and for the UK medical hashish market.
In June, Glass Pharms formally delivered its first crop to the primary UK-based clinic, marking the primary time {that a} domestically grown product has been made accessible to sufferers.
With the UK’s medical hashish market lengthy being hamstrung by provide points resulting from its reliance on imports, the supply of ‘dependable, repeatable, standardised drugs’ grown within the UK marks a key step ahead in decreasing friction.
To attain this, Glass Pharms says it has developed a ‘steady manufacturing mannequin’, which is able to harvest ‘each week of the yr’, considerably shortening the availability chain and permitting the corporate to offer recent flowers with ‘exacting requirements’ of terpene and cannabinoid profiles.
This steady manufacturing is just not set to alter following the launch of its personal branded merchandise, and provide to clinics together with Releaf stays the core pillar of the enterprise.
Glass Pharms defined to Enterprise of Hashish that its new providing is an ‘“and” quite than a brand new route’.
“So, you’ll see extra merchandise popping out with Glass Pharms, the place we’re primarily the cultivator for a spread of merchandise for particular clients. This stays core to our enterprise mannequin.
“This partnership below our personal model permits us to supply extra uncommon cultivars that we expect can fulfil real prescribing must the market with our pharmaceutical manufacturing accomplice.”
